US · IXHL · BIOTECHNOLOGY
Incannex Healthcare Limited (IXHL) intrinsic value and stock valuation
$1.86as of 2026-11-21 · Mkt cap 36.85M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Incannex Healthcare Limited DCF and intrinsic value
InvestorsCraft values IXHL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IXHL’s statements →
Incannex Healthcare Limited Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $90K | $10K | $0.00 | $790K | $1.9M |
| Operating income | -$-23.79M | -$-30.04M | -$-20.53M | -$-11.35M | -$-11.43M |
| Net income | -$-46.88M | -$-18.46M | -$-73.47M | -$-14.9M | -$-11.39M |
| EPSd | -$-40.77M | -$-3.42M | -$-14.32M | -$-1.5M | -$-1.4M |
| Operating cash flow | -$-12.51M | -$-15.85M | -$-16.18M | -$-12.85M | -$-6.87M |
| Capital expenditure | -$-10K | -$-280K | -$-480K | $0.00 | $0.00 |
| Free cash flow | -$-12.52M | -$-16.12M | -$-16.65M | -$-12.85M | -$-6.91M |
| Total assets | $20.5M | $17.1M | $35.8M | $38M | $9.32M |
| Total debt | $260K | $370K | $780K | $0.00 | $0.00 |
| Net debt | -$-14.78M | -$-5.49M | -$-32.51M | -$-37.63M | -$-9.12M |
| Total equity | $13.4M | $11.2M | $31.3M | $36M | $8.57M |
| Cash and short-term investments | $15M | $5.86M | $33.3M | $37.5M | $9.12M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $90K | $10K | $0.00 | $790K | $1.9M |
| Cost of revenue | $250K | $100K | $0.00 | $10K | $910K |
| Gross profit | -$-160K | $10K | $0.00 | $780K | $990K |
| Research and development expenses | $10.8M | $19.3M | $9.5M | $5.37M | $4.76M |
| Selling, general and administrative expenses | $13.1M | $25.6M | $11.9M | $10.2M | $7.7M |
| Other expenses | -$-250K | -$-14.79M | -$-900K | -$-3.42M | -$-40K |
| Operating expenses | $23.6M | $30.1M | $20.5M | $12.1M | $12.4M |
| Cost and expenses | $23.9M | $30.1M | $20.5M | $12.2M | $13.3M |
| Interest income | $60K | $310K | $360K | $10K | $0.00 |
| Interest expense | $300K | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $250K | $150K | $130K | $11.4M | $7.64M |
| Ebitda | -$-23.54M | -$-27.7M | -$-20.39M | -$-16.54M | -$-11.34M |
| Operating income | -$-23.79M | -$-30.04M | -$-20.53M | -$-11.35M | -$-11.43M |
| Total other income/expenses, net | -$-24.85M | $180K | -$-52.94M | -$-3.55M | $40K |
| Income before tax | -$-48.64M | -$-18.43M | -$-73.47M | -$-14.9M | -$-11.39M |
| Income tax expense | -$-1.76M | $30K | $0.00 | $0.00 | $0.00 |
| Net income | -$-46.88M | -$-18.46M | -$-73.47M | -$-14.9M | -$-11.39M |
| Weighted average shares outstanding | $1.15M | $5.39M | $5.13M | $9.93M | $8.15M |
| Weighted average diluted shares outstanding | $1.15M | $5.39M | $5.13M | $9.93M | $8.15M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $15M | $5.86M | $33.3M | $37.5M | $9.12M |
| Net receivables | $4.63M | $10M | $290K | $320K | $170K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $20M | $16.2M | $34.6M | $38M | $9.32M |
| Property, plant and equipment, net | $480K | $840K | $1.18M | $0.00 | $0.00 |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $480K | $840K | $1.18M | $0.00 | $0.00 |
| Total assets | $20.5M | $17.1M | $35.8M | $38M | $9.32M |
| Accounts payable | $6.07M | $530K | $2.63M | $1.31M | $230K |
| Short-term debt | $180K | $160K | $170K | $0.00 | $0.00 |
| Deferred revenue | $0.00 | $90K | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $6.98M | $5.62M | $3.84M | $2.02M | $760K |
| Long-term debt | $70K | $210K | $610K | $0.00 | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $70K | $210K | $610K | $0.00 | $0.00 |
| Capital lease obligations | $70K | $370K | $780K | $0.00 | $0.00 |
| Total liabilities | $7.06M | $5.83M | $4.45M | $2.02M | $750K |
| Common stock | $20K | $0.00 | $0.00 | $86.6M | $45.8M |
| Retained earnings | -$-157.56M | -$-110.67M | -$-138.79M | -$-59M | -$-43.95M |
| Accumulated other comprehensive income (loss) | -$-3.12M | -$-3.33M | -$-4.9M | $0.00 | $6.62M |
| Total equity | $13.4M | $11.2M | $31.3M | $36M | $8.57M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $260K | $370K | $780K | $0.00 | $0.00 |
| Net debt | -$-14.78M | -$-5.49M | -$-32.51M | -$-37.63M | -$-9.12M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-46.88M | -$-18.46M | -$-73.47M | -$-14.9M | -$-11.39M |
| Depreciation and amortization | $250K | $100K | $130K | $0.00 | $0.00 |
| Stock-based compensation | $2.61M | $8.93M | $3.23M | $1.47M | $600K |
| Change in working capital | $6.78M | -$-9.47M | -$-940K | $120K | $10K |
| Accounts receivable | $5.58M | $0.00 | $0.00 | -$-90K | $220K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $180K |
| Accounts payable | $1.39M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | -$-12.51M | -$-15.85M | -$-16.18M | -$-12.85M | -$-6.87M |
| Investments in property, plant and equipment | -$-10K | -$-280K | -$-480K | $0.00 | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $30K |
| Net cash used for investing activities | -$-10K | -$-280K | -$-480K | $0.00 | $30K |
| Common stock issued | $47.5M | $0.00 | $12.3M | $43.4M | $12.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $21.4M | $0.00 | $12.3M | $41.2M | $12.3M |
| Net change in cash | $9.18M | -$-16.26M | -$-5.59M | $28.4M | $5.8M |
| Cash at end of period | $15M | $5.86M | $33.3M | $37.6M | $9.12M |
| Operating cash flow | -$-12.51M | -$-15.85M | -$-16.18M | -$-12.85M | -$-6.87M |
| Capital expenditure | -$-10K | -$-280K | -$-480K | $0.00 | $0.00 |
| Free cash flow | -$-12.52M | -$-16.12M | -$-16.65M | -$-12.85M | -$-6.91M |
Line items
Line items
Line items
About Incannex Healthcare Limited
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
- CEO
- Joel Bradley Latham
- Employees
- 12
- Beta
- 2.71
Explore
Frequently asked questions
What is the intrinsic value of Incannex Healthcare Limited (IXHL)?
InvestorsCraft does not currently publish an intrinsic value for IXHL. How the IC value is calculated.
Is IXHL undervalued?
InvestorsCraft does not publish an undervaluation signal for IXHL at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.